Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

NCT02684617 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

75

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

rrCLL
rrMM
rrDLBCL

Interventions

BIOLOGICAL: pembrolizumab
DRUG: dinaciclib

Sponsor

Merck Sharp & Dohme LLC